AIA Group Ltd Lowers Stake in Thermo Fisher Scientific Inc. $TMO

AIA Group Ltd reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.2% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 86,693 shares of the medical research company’s stock after selling 5,759 shares during the quarter. Thermo Fisher Scientific comprises approximately 0.6% of AIA Group Ltd’s holdings, making the stock its 24th largest position. AIA Group Ltd’s holdings in Thermo Fisher Scientific were worth $42,612,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in TMO. High Note Wealth LLC boosted its stake in Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after purchasing an additional 29 shares in the last quarter. Swiss RE Ltd. bought a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $28,000. JPL Wealth Management LLC purchased a new position in Thermo Fisher Scientific in the third quarter worth about $28,000. Beacon Financial Strategies CORP bought a new position in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $29,000. Finally, Olistico Wealth LLC purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $29,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares in the company, valued at $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $532.17 on Friday. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a 12 month low of $403.36 and a 12 month high of $643.99. The stock has a market cap of $197.77 billion, a price-to-earnings ratio of 29.26, a PEG ratio of 2.36 and a beta of 0.87. The company’s 50 day moving average is $484.57 and its two-hundred day moving average is $514.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business had revenue of $11.01 billion for the quarter, compared to analysts’ expectations of $10.86 billion. During the same period last year, the firm earned $5.15 earnings per share. The business’s quarterly revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.34%.

Wall Street Analyst Weigh In

Several analysts have commented on TMO shares. Piper Sandler assumed coverage on Thermo Fisher Scientific in a research note on Thursday, June 11th. They set a “neutral” rating and a $510.00 target price on the stock. Barclays lowered their price target on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a report on Tuesday, April 14th. DZ Bank started coverage on Thermo Fisher Scientific in a report on Friday, March 27th. They issued a “buy” rating and a $610.00 price objective for the company. Wall Street Zen lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Wolfe Research assumed coverage on shares of Thermo Fisher Scientific in a report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $602.14.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.